Chronic Idiopathic Constipation Treatment Market

Chronic idiopathic constipation is a highly prevalent functional bowel disorder that affects millions of individuals worldwide. Some of the major factors that contribute to the burgeoning number of patients suffering from chronic idiopathic constipation include sedentary lifestyle, increasing usage of anti-inflammatory agents, and drastic decline in the intake of dietary fibers. Over the past few years, considerable efforts have been made to improve the management of chronic idiopathic constipation.

Chronic Idiopathic Constipation Treatment Market contains market size and forecasts of Chronic Idiopathic Constipation Treatment in Global, including the following market information:

Global Chronic Idiopathic Constipation Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Chronic Idiopathic Constipation Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Blood Tests Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Chronic Idiopathic Constipation Treatment include Bayer AG, Allergan, Bausch Health, Sanofi, Takeda Pharmaceutical Company, SEBELA PHARMACEUTICALS, Ironwood Pharmaceuticals, Inc., Albireo Pharma, Inc. and Sucampo Pharmaceuticals, Inc. (Mallinckrodt) and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Chronic Idiopathic Constipation Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Chronic Idiopathic Constipation Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Chronic Idiopathic Constipation Treatment Market Segment Percentages, by Type, 2021 (%)

Blood Tests

Sigmoidoscopy

Colonoscopy

Balloon Expulsion Test

Anorectal Manometry

Colonic Transit Study

Defecography

Others

Global Chronic Idiopathic Constipation Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Chronic Idiopathic Constipation Treatment Market Segment Percentages, by Application, 2021 (%)

Hospitals

Gastroenterology clinics

Diagnostic Centers

Others

Global Chronic Idiopathic Constipation Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Chronic Idiopathic Constipation Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Chronic Idiopathic Constipation Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Chronic Idiopathic Constipation Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Bayer AG

Allergan

Bausch Health

Sanofi

Takeda Pharmaceutical Company

SEBELA PHARMACEUTICALS

Ironwood Pharmaceuticals, Inc.

Albireo Pharma, Inc.

Sucampo Pharmaceuticals, Inc. (Mallinckrodt)

Janssen Pharmaceuticals, Inc. (Johnson and Johnson)